Skip to main content

Table 2 Advanced lipid analysis

From: Clinical characterization of familial hypercholesterolemia due to an amish founder mutation in Apolipoprotein B

 

Reference Range

Controls

(n = 9)

ApoBR3500Q

P-value

Heterozygotes

(n = 13)

Homozygotes

(n = 3)

ApoB (mg/dL)

 < 60

65 (42–103)

117 (77–147)

246 (179–250)

0.001

ApoB:ApoA-1

 ≤ 0.60

0.5 (0.3–0.8)

0.8 (0.6–1.2)

1.7 (1.5–1.9)

 < 0.001

LDL-P (nmol/L)

 < 1020

1085 (597–1578)

1818 (1216–2369)

NA

0.001

sdLDL-P (mg/dL)

 < 21

17 (10–28)

32 (16–46)

47 (33–62)

0.003

sdLDL-C (% of LDL)

 < 26

18 (16–22)

17 (15–24)

16 (10–20)

0.375

Lp(a)-P (nmol/L), n (%) ≥ 75

 < 75

4 (44)

4 (31)

NA

0.662

ApoA-1 (mg/dL)

 > 150

143 (119–170)

137 (107–168)

135 (119–143)

0.214

HDL-P (umol/L)

 > 38

32.8 (31.0–39.8)

35.1 (29.1–42.8)

NA

0.987

HDL2-C (mg/dL)

 ≥ 17

35 (14–50)

24 (10–52)

19 (14–38)

0.269

  1. Fasting apolipoproteins and small particle analysis for ApoBR3500Q heterozygotes and homozygotes and age-matched sibling controls. P-values pertain to comparisons of controls and ApoBR3500Q heterozygotes. ApoBR3500Q homozygotes are included for completeness but not included in statistical analysis. Median (min–max) compared by the exact Wilcoxon rank-sum test unless noted. Fisher’s exact test used where n (%) reported
  2. ApoB, Apolipoprotein B; ApoA-1, Apolipoprotein A-1; LDL-P, Low-density lipoprotein particles; sdLDL-C, Small, dense low density lipoprotein cholesterol; Lp(a)-P, Lipoprotein(a) particles; HDL-P, High density lipoprotein particles; HDL2-C, High-density lipoprotein 2 cholesterol; NA, Insufficient data to report
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us